CCII 京都大学大学院医学研究科附属 がん免疫総合研究センター

  1. Home
  2. 研究
  3. 研究部門、ラボ & 研究者
  4. がん免疫多細胞システム制御部門　
  5. 西川 博嘉 教授

西川 博嘉 教授
がん免疫多細胞システム制御部門

学歴

  • 1995: 三重大学医学部医学科卒業
  • 1998-2002: 三重大学大学院医学研究科内科学専攻

職歴

  • 2002-2003: 三重大学医学部附属病院　内科医員
  • 2003-2006: Memorial Sloan Kettering Cancer Centerリサーチフェロー
  • 2006-2010: 三重大学大学院医学系研究科 病態解明医学講座 講師
  • 2010-2015: 大阪大学免疫学フロンティア研究センター 実験免疫学 特任准教授
  • 2012-2015: Department of Oncology, Roswell Park Cancer Institute, Adjunct Associate Professor（兼任）
  • 2015~: 国立がん研究センター 研究所　腫瘍免疫研究 分野長／先端医療開発センター 免疫TR分野 分野長
  • 2016~: 名古屋大学大学院医学系研究科　微生物・免疫学講座　分子細胞免疫学教授 (クロスアポイントメント)
  • 2024~: 京都大学大学院医学研究科附属がん免疫総合研究センター がん免疫多細胞システム制御部門 教授 (クロスアポイントメント)

受賞

所属学会

編集委員会

Selected Publications

Original Articles

1. Itahashi K, IrieT, Yuda J, Kumagai S, Tanegashima T, Lin Y-Z, Watanabe S, Goto Y, Suzuki J, Aokage K, Tsuboi M, Minami Y, Ishii G, Ohe Y, Ise W, Kurosaki T, Suzuki Y, Koyama S, and Nishikawa H: BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors. Sci Immunol. 14;7(76):eabk0957 2022.

2. Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin, Y-T, Togashi Y, Kamada T, Irie T, Okumura G, Kohno H, Ito D, Fujii R, Watanabe S, Sai A, Fukuoka S, Sugiyama E, Watanabe G, Owari T, Nishinakaumra H, Sugiyama D, Maeda Y, Kawazoe A, Yukami H, Cida K, Ohara Y, Yoshida T, Shinno Y, Takeyasu Y, Shirasawa M, Nakama K, Aokage K, Suzuki J, Ishii G, Kuwata T, Sakamoto N, Kawazu M, Ueno T, Mori T, Yamazaki N, Tsuboi M, Yatabe Y, Kinoshita T, Doi T, Shitara K, Mano H, and Nishikawa H: Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. Jan 25:S1535-6108(22)00003-4 2022. DOI: https://doi.org/10.1016/j.ccell.2022.01.001

3. Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, and Nishikawa H: Depletion of central memory CD8 + T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nat Commun. 12(1):7280 2021. DOI: 10.1038/s41467-021-27574-0

4. Takeuchi Y, Tanegashima T, Sato E, Irie T, Sai A, Itahashi K, Kumagai S, Tada Y, Togashi Y, Koyama S, Akbay E.A, Karasaki T, Kataoka K, Funaki S, Shintani Y, Nagatomo I, Kida H, Ishii G, Miyoshi T, Aokage K, Kakimi K, Ogawa S, Okumura M, Eto M, Kumanogoh A, Tsuboi M, and Nishikawa H: Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. Sci Immunol.6(65):eabc6424 2021. DOI: https://doi.org/10.1126/sciimmunol.abc6424

5. Kumagai S, TogashiY, Kamada T, Sugiyama E, Nishinakaumra H, Takeuchi Y, Kochin, V, Itahashi K, Maeda Y, Matsui S, Shibahara,T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, KawazuM, UenoT, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, and Nishikawa H: The PD-1expression balance between effector and regulatory T cell predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol.21(11):1346-1358 2020.

6. Kumagai S, Togashi Y, Sakai C, Kawazoe A, Kawazu M, Ueno T, Sato E, Kuwata T, Kinoshita T, Yamamoto M, Nomura S, Tsukamoto T, Mano H, Shitara K, and Nishikawa H: An oncogenic alteration creates a tumor microenvironment that promotes tumor progression by conferring a metabolic advantage to regulatory T cells. Immunity. 53(1):187-203.e8 2020. DOI: 10.1016/j.immuni.2020.06.016

7. Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, Shintani Y, Okumura M, Tsuboi M, and Nishikawa H:Blockade of EGFR improves responsiveness to PD1 blockade in EGFR-mutated non-small cell lung cancer. Sci Immunol. 5 (43). pii: eaav3937 2020. DOI: https://doi.org/10.1126/sciimmunol.aav3937

8. Tokunaga A, Sugiyama D, Maeda Y, Warner AB, Panageas KS, Ito S, Togashi Y, Sakai C, Wolchok JD, and Nishikawa H: Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. J Exp Med. 216(12):2701-2713 2019. DOI: 10.1084/jem.20190738

9. Saito T, Nishikawa H (Co-corresponding author), Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E, Nagase H, Nishimura J, Yamamoto H, Takiguchi S, Tanoue T, Suda W, Morita H, Hattori M, Honda K, Mori M, Doki Y, Sakaguchi S: Two FOXP3+CD4+ T-cell subpopulations distinctly control the prognosis of colorectal cancers. Nat Med. 22 (6):679-684 2016. DOI: 10.1038/nm.4086

10. Maeda Y, Nishikawa H (Co-corresponding author), Sugiyama D, Ha D, Hamaguchi M, Saito T, Nishioka M, Wing JB, Adeegbe D, Katayama I, Sakaguchi S: Detection of self-reactive CD8+　T cells with an anergic phenotype in healthy individuals. Science. 346(6216):1536-1540 2014. DOI: 10.1126/science.aaa1292

Review Articles

1. Kumagai S, Itahashi K, and Nishikawa H: Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno‑genomic paradigm for precision medicine. Nat Rev Clin Oncol. 21(5):337-353 2024. DOI: 10.1038/s41571-024-00870-6

2. Itahashi K, Irie T, and Nishikawa H: Regulatory T-cell development in the tumor microenvironment. Eur J Immunol. 52(8):1216-1227 2022. DOI: 10.1002/eji.202149358

3. Kumagai S, Koyama S, and Nishikawa H: Antitumour immunity regulated by aberrant ERBB family signalling. Nat Rev Cancer. 21(3):181-197 2021. DOI: 10.1038/s41568-020-00322-0

4. Koyama S, Nishikawa H: Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 9(7):e002591 2021. DOI: 10.1136/jitc-2021-002591

5. Togashi Y, Shitara K, and Nishikawa H: Regulatory T cells in cancer immunosuppression – Implications for anticancer therapy. Nat Rev Clin Oncol.16(6):356-371 2019. DOI: 10.1038/s41571-019-0175-7

WordPress Lightbox